Small Biotech Companies Could Get Faster USPTO Review Of COVID-19 Patent Applications
Executive Summary
Pilot program aims to examine applications for COVID-19 products subject to approval by FDA within 6 to 12 months; the prioritized examination is available solely for small entities and would save them $2,000.